Advertisement

ViewpointIn-Press Preview Free access | 10.1172/JCI148832

SARS-Cov2 variants and convalescent plasma: reality, fallacies, and opportunities

Arturo Casadevall,1 Jeffrey Henderson,2 Michael Joyner,3 and Liise-anne Pirofski4

1Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, United States of America

2Department of Medicine and Molecular Microbiology, Washington University in St. Louis School of Medicine, St. Louis, United States of America

3Department of Anesthesiology and Periopertive Medicine, Mayo Clinic, Rochester, United States of America

4Departments of Medicine, Microbiology and Immunology, Albert Einstein College of Medicine, New York, United States of America

Find articles by Casadevall, A. in: JCI | PubMed | Google Scholar |

1Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, United States of America

2Department of Medicine and Molecular Microbiology, Washington University in St. Louis School of Medicine, St. Louis, United States of America

3Department of Anesthesiology and Periopertive Medicine, Mayo Clinic, Rochester, United States of America

4Departments of Medicine, Microbiology and Immunology, Albert Einstein College of Medicine, New York, United States of America

Find articles by Henderson, J. in: JCI | PubMed | Google Scholar |

1Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, United States of America

2Department of Medicine and Molecular Microbiology, Washington University in St. Louis School of Medicine, St. Louis, United States of America

3Department of Anesthesiology and Periopertive Medicine, Mayo Clinic, Rochester, United States of America

4Departments of Medicine, Microbiology and Immunology, Albert Einstein College of Medicine, New York, United States of America

Find articles by Joyner, M. in: JCI | PubMed | Google Scholar

1Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, United States of America

2Department of Medicine and Molecular Microbiology, Washington University in St. Louis School of Medicine, St. Louis, United States of America

3Department of Anesthesiology and Periopertive Medicine, Mayo Clinic, Rochester, United States of America

4Departments of Medicine, Microbiology and Immunology, Albert Einstein College of Medicine, New York, United States of America

Find articles by Pirofski, L. in: JCI | PubMed | Google Scholar

Published February 23, 2021 - More info

J Clin Invest. https://doi.org/10.1172/JCI148832.
Copyright © 2021, American Society for Clinical Investigation
Published February 23, 2021 - Version history
View PDF
Abstract

In recent months genomic characterization of pandemic SARS-CoV-2 isolates identified viral variants that are less susceptible to neutralization by convalescent plasma (CP), vaccine-elicited plasma/sera, or SARS-CoV-2 monoclonal antibodies than earlier SARS-CoV-2 strains. In this Viewpoint, Casadevall et al. argue against the causal association made in some press articles between the emergence of SARS-CoV-2 variants and convalescent plasma use.

Version history
  • Version 1 (February 23, 2021): In-Press Preview
Advertisement
Advertisement